Viread (Tenofovir)
| Brand Name: |
Viread |
| Generic Name: |
Tenofovir disoproxil fumarate, TDF |
| Adult Single Dose: |
One 300-mg tablet (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Viread (Tenofovir) (September 21, 2012)
From AIDSinfo
- Viread (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Tenofovir (Viread) (January 21, 2012)
To read PDF, click here.
From AIDS InfoNet
- Patient Information About Viread (Tenofovir) (PDF) (January 2012)
From Gilead Sciences, Inc.
- Viread (Tenofovir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Tenofovir (Viread) (August 15, 2006)
From AIDS Treatment Data Network
- Viread (Tenofovir) (November 2005)
To read PDF, click here.
From The Center for AIDS
- Drug Interactions: Tenofovir (August 2004)
From Project Inform
- Gilead's Viread International Access Program (May 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tenofovir: New Kind of Anti-HIV Drug Gets Approved (March 2002)
In Project Inform Perspective, from Project Inform
VIEW ALL ARTICLES
News
 Tenofovir Linked With Risk of Kidney Damage (February 21, 2012)
In Positively Aware, from Test Positive Aware Network
- Tenofovir Label Extended to Pediatric Indication (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Viread: New Formulation and Pediatric Dosing Update (January 19, 2012)
From U.S. Food and Drug Administration
- Scientists "Tinker" With HIV Drug Chemistry Hoping to Reduce Costs (May 13, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Expanded Indication for Viread, to Include the Treatment of Patients 12 to Less Than 18 Years of Age (March 24, 2010)
From U.S. Food and Drug Administration
- FDA Approves Gilead's Antiretroviral Viread for Use as Hepatitis B Treatment (August 13, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Gilead Sciences May Lose Patent for Viread (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works
- U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Viread (Tenofovir Disoproxil Fumarate) Labeling Revision (May 13, 2005)
Among the revisions is updated information regarding drug resistance and long-term effects on bone mineral density.
From U.S. Food and Drug Administration
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
